Wave Life Sciences Ltd.

NasdaqGM:WVE Rapporto sulle azioni

Cap. di mercato: US$716.0m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Wave Life Sciences Gestione

Gestione criteri di controllo 3/4

Wave Life Sciences' Il CEO è Paul B. Bolno, nominato in Dec2013, e ha un mandato di 10.67 anni. la retribuzione annua totale è $ 3.87M, composta da 16.4% di stipendio e 83.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.33% delle azioni della società, per un valore di $ 2.38M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.7 anni e 7.8 anni.

Informazioni chiave

Paul B. Bolno

Amministratore delegato

US$3.9m

Compenso totale

Percentuale dello stipendio del CEO16.4%
Mandato del CEO10.7yrs
Proprietà del CEO0.3%
Durata media del management3.7yrs
Durata media del Consiglio di amministrazione7.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Mar 09

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Wave Life Sciences Q2 2022 Earnings Preview

Aug 10

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Sep 24
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Aug 07
What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Wave Life Sciences posts proof-of-concept data from genetic disorder study

Jun 02

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

May 15
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Apr 02
Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul B. Bolno rispetto agli utili di Wave Life Sciences?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$62m

Dec 31 2023US$4mUS$636k

-US$58m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

-US$131m

Mar 31 2023n/an/a

-US$151m

Dec 31 2022US$3mUS$618k

-US$162m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$120m

Mar 31 2022n/an/a

-US$118m

Dec 31 2021US$4mUS$597k

-US$122m

Sep 30 2021n/an/a

-US$116m

Jun 30 2021n/an/a

-US$143m

Mar 31 2021n/an/a

-US$145m

Dec 31 2020US$1mUS$579k

-US$150m

Sep 30 2020n/an/a

-US$178m

Jun 30 2020n/an/a

-US$196m

Mar 31 2020n/an/a

-US$197m

Dec 31 2019US$4mUS$579k

-US$194m

Sep 30 2019n/an/a

-US$175m

Jun 30 2019n/an/a

-US$162m

Mar 31 2019n/an/a

-US$156m

Dec 31 2018US$6mUS$541k

-US$147m

Sep 30 2018n/an/a

-US$140m

Jun 30 2018n/an/a

-US$127m

Mar 31 2018n/an/a

-US$116m

Dec 31 2017US$3mUS$515k

-US$102m

Compensazione vs Mercato: La retribuzione totale di Paul B. ($USD 3.87M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 3.30M ).

Compensazione vs guadagni: La retribuzione di Paul B. è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Paul B. Bolno (50 yo)

10.7yrs

Mandato

US$3,874,300

Compensazione

Dr. Paul B. Bolno, M.D., MBA served as an Independent Director at SQZ Biotechnologies Company since June 2020 until March 2024. Since May 2020 he has served as Chairman of the Scientific Advisory Group for...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Paul B. Bolno
President10.7yrsUS$3.87m0.29%
$ 2.1m
Kyle B. Moran
CFO & Principal Accounting Officer3.7yrsUS$1.70m0.014%
$ 98.4k
Chandra Vargeese
Chief Technology Officer4.3yrsUS$1.78m0.15%
$ 1.1m
Erik Ingelsson
Chief Scientific Officerless than a yearNessun datoNessun dato
Kate Rausch
Head of Investor Relations5.3yrsNessun datoNessun dato
Linda Rockett
Senior VP & General Counsel8.3yrsNessun datoNessun dato
Christopher Francis
Senior VP of Corporate Development & Head of Emerging Areas7.6yrsUS$1.68m0.064%
$ 457.6k
Daryn Lewis
Senior VP & Head of Human Resources1.6yrsNessun datoNessun dato
Sridhar Vaddeboina
Senior Vice President of Chemistry2.8yrsNessun datoNessun dato
Anne-Marie Li-Kwai-Cheung
Chief Development Officer1.8yrsNessun datoNessun dato
Hsiu-Chiung Yang
Senior Vice President of Translational Medicine1.6yrsNessun datoNessun dato

3.7yrs

Durata media

51.5yo

Età media

Gestione esperta: Il team dirigenziale di WVE è considerato esperto (durata media dell'incarico 3.7 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Paul B. Bolno
President10.3yrsUS$3.87m0.29%
$ 2.1m
Gregory L. Verdine
Director11.1yrsUS$170.74k0.024%
$ 172.2k
Mark H. Corrigan
Independent Director4.9yrsUS$194.74k0.095%
$ 680.2k
Christian O. Henry
Independent Chairperson7.8yrsUS$222.24k0.10%
$ 740.5k
Adrian G. Rawcliffe
Independent Director7.5yrsUS$188.74k0.10%
$ 740.5k
Peter Kolchinsky
Independent Director9.6yrsUS$170.74kNessun dato
Ken Takanashi
Independent Director12.1yrsUS$170.74k0%
$ 0
Heidi L. Wagner
Independent Director4.9yrsUS$185.74k0.095%
$ 680.2k
Aik Na Tan
Independent Director4yrsUS$172.24k0.085%
$ 606.0k

7.8yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di WVE sono considerati esperti (durata media dell'incarico 7.8 anni).